EMA releases updated guidance on drug shortage prevention plans

The European Medicines Agency has published a revised guideline aimed at helping marketing authorisation holders develop and keep drug shortage prevention plans for their products.

The new guidance clarifies expectations for the content and maintenance of these plans, aligning them with the agency’s legal deadline for submission.

Companies will need to review their existing procedures to ensure compliance, which the EMA says should improve the availability of medicines across the EU.